The Network between Heart and Liver from the View of Persian Medicine Versus Conventional Medicine
AbstractBackground: Liver and Heart are two important organs in the human body, whose function strongly affects other organs. On the other hand, these two main organs affect each other due to common metabolic pathways. Therefore, a disorder in any of them can lead to disease in other organs. Today, using the network medicine perspective, these complex connections can be easily mapped and discovered. From the Persian medicine viewpoint, links are formed based on the material causes of diseases, while from the conventional medicine viewpoint, they are mostly formed due to metabolites, genes, and pathways. Materials and methods: In this article, we first investigated the recent articles of conventional medicine that examine the relationship between Heart and Liver in the important databases. Then we checked out the sources of Persian medicine and finally, using the RStudio software used in network medicine for text mining, we drew the communication network centered on Heart and liver and their mutual causes from the perspective of Persian Medicine. Results: Examining the network connection between the heart and the liver showed that the definitions based on Persian medicine, which are based on the material causes of diseases, are very compatible with the genes, metabolites and pathways between these two organs. Conclusion: understanding these concepts can be helpful in detecting the co-occurrence of diseases of these two organs, as well as predicting the possible occurrence of related diseases between the heart and liver, and ultimately in better treatment.[GMJ.2023;12:e2557]
Zeb I, Li D, Budoff MJ, Katz R, Lloyd-Jones D, Agatston A, et al. Nonalcoholic fatty liver disease and incident cardiac events: the multi-ethnic study of atherosclerosis. JACC . 2016;67(16):1965-6.
VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62(3):773-83.
Vita T, Murphy DJ, Osborne MT, Bajaj NS, Keraliya A, Jacob S, et al. Association between nonalcoholic fatty liver disease at CT and coronary microvascular dysfunction at myocardial perfusion PET/CT. Radiology. 2019;291(2):330-7.
Ito M, Adachi-Akahane S. Inter-organ communication in the regulation of lipid metabolism: focusing on the network between Liver, intestine, and Heart. Journal of pharmacological sciences. 2013:13R09CP.
Ambale Venkatesh B, Lima JA. Probing Liver Heart Axis. Radiological Society of North America. 2019;291(2):338-9.
Baskin KK, Bookout AL, Olson EN. The Heart-liver metabolic axis: defective communication exacerbates disease. EMBO molecular medicine. 2014;6(4):436-8.
Avicenna (Ibn Sina). The canon of medicine. Beirut, Lebanon: Institute Dare Ehya al-Toras; 2005.
Azam Khan M. Exir Azam [Persian] Tehran,Iran: Institute of Meical History, Islamic Medicine and Complementary Medicine; 2008.
Zargaran A, Mehdizadeh A, Zarshenas MM, Mohagheghzadeh A. Avicenna (980-1037 AD). Journal of neurology. 2012;259(2):389-90.
Aghili Shirazi MH. Moalejat-e Aghili (Persian). Tehran: Institute of Meical History, Islamic Medicine and Complementary Medicine; 2008.
Chou E. Mastering Python Networking. Birmingham: Packt Publishing Ltd; 2017.
Kronthaler F, Zöllner S. Data Analysis with RStudio: Springer; 2021.
Shirbeigi L, Zarei A, Naghizadeh A, Vaghasloo MA. The concept of temperaments in traditional Persian medicine. Traditional and Integrative Medicine. 2017:143-56.
Zarei A, Noroozi S, Khadem E. A Review on the Structure and Function of Liver from Avicenna Point of View and Its Comparison with Conventional Medicine. Traditional and Integrative Medicine. 2019;18:28-36.
Zarei A, Rezaeizadeh H, Karimi M. Persian Medicine Perspective on the Network Between Liver and Other Organs. Hepatitis Monthly. 2021;21(11):e123088.
Rezadoost H, Karimi M, Jafari M. Proteomics of hot-wet and cold-dry temperaments proposed in Iranian traditional medicine: a Network-based Study. Scientific reports. 2016;6(1):1-8.
Jorjani E. zakhire kharazmshahi[in persian]. Tehran: Iranian Medical Academy; 2001.
Aghili M. Kholase al hekmah. Quom, Iran: Esmailian. 2006:35-42.
Kermani N-I-E. Sharh-al-Asbab V-al-Alamaat. Tehran: Tehran University of Medical Sciences; 2004.
Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic Heart failure: prevalence, characteristics and prognostic significance. European journal of clinical investigation. 2012;42(2):153-63.
Kazantzis M, Stahl A. Fatty acid transport proteins, implications in physiology and disease. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2012;1821(5):852-7.
Vela D. Balance of cardiac and systemic hepcidin and its role in Heart physiology and pathology. Laboratory investigation. 2018;98(3):315-26.
Hernandez-Anzaldo S, Berry E, Brglez V, Leung D, Yun TJ, Lee JS, et al. Identification of a novel Heart-liver axis: matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate lipid metabolism and inflammation in Liver. Journal of the American Heart Association. 2015;4(11):e002553.
Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Kawamoto A, et al. Analysis of liver metabolism in a rat model of Heart failure. International journal of cardiology. 2012;161(3):130-6.
Tang T-T, Li Y-Y, Li J-J, Wang K, Han Y, Dong W-Y, et al. Liver-Heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction. Theranostics. 2018;8(16):4552.
Mantovani A. Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of Liver-Heart axis. Journal of clinical and translational hepatology. 2017;5(2):134.
Ambale Venkatesh B, Lima JA. Probing Liver Heart Axis. Radiological Society of North America. 2019;291(2): 338-9.
Mukhopadhyay R. Mouse models of atherosclerosis: explaining critical roles of lipid metabolism and inflammation. Journal of applied genetics. 2013;54(2):185-92.
Yilmaz Y, Kurt R, Yonal O, Polat N, Celikel CA, Gurdal A, et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis. 2010;211(1):182-6.
Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, et al. Association of liver fibrosis with cardiovascular diseases in the general population: the multi-ethnic study of atherosclerosis (MESA). Circulation: Cardiovascular Imaging. 2018;11(3):e007241.
de Bold AJ. Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. Canadian journal of physiology and pharmacology. 2011;89(8):527-31.
Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in Heart failure and its relation to the severity of tricuspid regurgitation. American Journal of Cardiology. 2002;90(12):1405-9.
Vasconcelos LABA, Almeida EAd, Bachur LF. Clinical evaluation and hepatic laboratory assessment in individuals with congestive Heart failure. Arquivos brasileiros de cardiologia. 2007;88:590-5.
Correale M, Tarantino N, Petrucci R, Tricarico L, Laonigro I, Di Biase M, et al. Liver disease and Heart failure: Back and forth. European Journal of Internal Medicine. 2018;48:25-34.
Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and Heart failure. International Journal of Angiology. 2011;20(03):135-42.
Yamada T, Kotake Y, Nagata H, Takeda J. Atrial natriuretic peptide reduces hepatic ischemia-reperfusion injury in rabbits. Journal of anesthesia. 2013;27(6):901-8.
Noghani MT, Namdar H. Migraine associated with gastrointestinal disorders: a pathophysiological explanation. Medical hypotheses. 2019;125:90-3.
Horvatits T, Drolz A, Rutter K, Roedl K, Kluge S, Fuhrmann V. Hepatocardiac disorders. World J Hepatol. 2014;6(1):41-54.
Nakamura M, Sadoshima J. Heart over mind: metabolic control of white adipose tissue and liver. EMBO Molecular Medicine. 2014;6(12):1521-4.
Ghaderi. Fosool-Ol-Aaraz. Tehran: Iran University of Medical Sciences; 2008.
Ibn-abbas A. Kamel-Al-sana-ah-Al-Tebbiah. Qom: Jalal-el-Din; 2008.
Copyright (c) 2023 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).